MiMedx Group, Inc. (MDXG) company profile
Close on Nov 18, 2026Market cap $464.04MP/E –Yield –
About MiMedx
Surgical & Medical Instruments & Apparatus, SIC 3841
MIMEDX develops and manufactures regenerative biomaterial products, primarily human placental allografts, animal-derived xenografts, and advanced wound dressings. The company operates across wound care, surgical specialties, and burn treatment sectors. Its product portfolio includes human placental membrane allografts, bovine collagen matrices, autologous platelet-rich plasma gels, and peptide matrices intended to assist in healing chronic wounds, surgical recovery, and internal tissue reinforcement. Customers include clinicians, hospitals, private physician practices, wound care clinics, ambulatory surgery centers, nursing homes, and federal healthcare facilities such as the Department of Veterans Affairs.
The company conducts most of its commercial business in the United States and distributes products internationally, including in Japan. It processes donated human birth tissue from a nationwide network of partner hospitals at manufacturing facilities located in Marietta and Kennesaw, Georgia, while the provided text does not state its headquarters location. Through December 2025, the business has supplied several million allografts and maintains nearly three hundred issued and pending patents worldwide.
Summary of the business section of MiMedx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- MiMedx Group, Inc.
- Headquarters
- Marietta, GA
- Address
- 1775 W Oak Commons Court, Ne 30062
- Phone
- (770) 651-9100
- Website
- mimedx.com
- Employees
- 808, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- MDXG
- Exchange
- Nasdaq
- IPO date
- Feb 12, 2008
- Shares outstanding
- 146M, Oct 22, 2026
- Public float
- $719.00M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1376339
- CUSIP
- 602496101
- ISIN
- US6024961012
- FIGI
- BBG000RJ6FL5
- Share class FIGI
- BBG001STPW96
- EIN
- 26-2792552
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rice Doug | Chief Financial Officer | 399,566 |
| Kimberly Maersk-Moller | Chief Commercial Officer | 309,630 |
| William Frank Hulse IV | General Counsel and CAO | 543,195 |
| Ricci S. Whitlow | Chief Operating Officer | 462,825 |
| Joseph H. Capper | Chief Executive Officer | 904,656 |
| James L. Bierman | Director | 263,684 |
| Tiffany Olson | Director | 108,510 |
| William A. Hawkins | Director | 255,431 |
| Todd Newton | Director | 463,684 |
| Dorothy E. Puhy | Director | 108,510 |
| M. Kathleen Behrens | Director | 212,771 |
| Cato T. Laurencin | Director | 181,923 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.18M | -$14.96M | $2.10M | $75 | – |
| FY2024 Joseph H.Capper | $1.39M | $5.12M | $2.77M | $106 | – |
| FY2024 K.Todd Newton | – | $487.29K | $2.77M | $106 | – |
| FY2023 Joseph Capper | $20.83M | $37.01M | $2.52M | $97 | – |
| FY2023 Joseph H.Capper | $20.76M | $36.93M | $2.52M | $97 | – |
| FY2023 K.Todd Newton | $295.29K | $487.29K | $2.52M | $97 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Joseph H. Capper Chief Executive Officer | $768.17K | $4.70M | $819.42K | $887.80K | $7.81K | $7.18M | +417% |
| Doug Rice Chief Financial Officer | $540.00K | $966.64K | $168.57K | $372.60K | $71.92K | $2.12M | -11% |
| William F. Hulse IV General Counsel and Chief Administrative Officer | $546.00K | $977.38K | $170.44K | $376.74K | $74.93K | $2.15M | -11% |
| Ricci S. Whitlow EVP & Chief Operating Officer | $540.00K | $966.64K | $168.57K | $372.60K | $13.14K | $2.06M | -10% |
| Kimberly Maersk-Moller Chief Commercial Officer | $540.00K | $966.64K | $168.57K | $372.60K | $9.04K | $2.06M | -48% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 808 full time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?